RX-3341: Phase II started

Rib-X began a double-blind, U.S. Phase II trial (RX-3341-201) to compare 2 dose strengths of intravenous RX-3341 vs. intravenous Tygacil tigecycline for 5-14 days in 150 hospitalized patients with cSS...